Onyx Biotec IPO - Day 3 Subscription at 23.88 Times

Onyx Biotec's initial public offering (IPO) has received overwhelming investor interest over the three-day period. The IPO witnessed exceptional growth in demand, with subscription rates growing from 3.15 times on day one, to 9.95 times on day two, and reaching an impressive 23.88 times by 11:21 AM on the final day.

Onyx Biotec IPO, which opened on 13th November 2024, has seen enthusiastic participation across categories. The Retail Investors segment has shown exceptional interest reaching 35.70 times subscription, while Non-Institutional Investors demonstrated strong participation at 28.06 times. The QIB portion is yet to see participation.

This strong response comes amid positive sentiment in the Indian stock market, particularly towards companies in the pharmaceutical sector.

Subscription Status of Onyx Biotec IPO:

*As of 11:21 AM
Here are the subscription details for Onyx Biotec IPO as of Day 3 (18th November 2024, 11:21 AM):
 

Note:

• "Shares Offered" and "Total Amount" are calculated based on the upper price of the issue price range.
• The portion of anchor investors and market makers is not included in the total shares offered.

Key Highlights:

• Overall subscription reached an impressive 23.88 times, showing exceptional investor confidence
• Retail investors led with an overwhelming 35.70 times subscription
• Non-institutional investors showed robust interest with 28.06 times subscription
• QIB portion remained unsubscribed
• Total applications reached 30,415 with strong retail participation
• The subscription trend indicates exceptional investor response across categories

Onyx Biotec IPO - Day 2 Subscription at 9.95 Times

Key Highlights:

• Overall subscription improved to 9.95 times, showing strong momentum
• Retail investors demonstrated strong interest with 16.40 times subscription
• Non-institutional investors showed good participation at 8.15 times
• QIB portion remained unsubscribed
• The subscription trend indicated building investor confidence

Onyx Biotec IPO - Day 1 Subscription at 3.15 Times

Key Highlights:

• Overall subscription reached 3.15 times on the opening day, showing a strong initial response
• Retail investors showed robust interest with 5.57 times subscription
• Non-institutional investors demonstrated good interest with 1.70 times subscription
• QIB portion remained unsubscribed
• The subscription trend indicated strong retail confidence on day one

About Onyx Biotec Limited

Incorporated in May 2005, Onyx Biotec Limited has established itself as a specialized pharmaceutical manufacturer focusing on sterile water for injections and contract manufacturing services. The company operates two state-of-the-art manufacturing facilities in Solan, Himachal Pradesh, with Unit I having a daily production capacity of 638,889 units of Sterile Water for Injections and Unit II producing 40,000 units of dry powder injections and 26,667 units of dry syrup per shift.

The company has built an impressive client portfolio including leading pharmaceutical companies such as Hetero Healthcare, Mankind Pharma, Sun Pharmaceutical, and Aristo Pharmaceuticals. As of May 31, 2024, their client base exceeded 100 Indian and multinational pharmaceutical companies. The company's commitment to quality is reflected in its ISO 9001:2015 and ISO 14001:2015 certifications from ROHS Certification Private Limited.

Operating with 175 employees across various departments as of July 31, 2024, the company has demonstrated strong financial performance with a 35.99% revenue increase and 64.35% profit after tax growth between FY2023 and FY2024.

Highlights of the Onyx Biotec IPO

• IPO type: Book Built Issue
• IPO size: ₹29.34 crores
• Fresh Issue: 48.10 lakh shares
• Face value: ₹10 per share
• Price band: ₹58 to ₹61 per share
• Lot size: 2,000 shares
• Minimum investment for retail investors: ₹122,000
• Minimum investment for HNI: ₹244,000 (2 lots)
• Listing at: NSE SME
• IPO opens: November 13, 2024
• IPO closes: November 18, 2024
• Allotment date: November 19, 2024
• Listing date: November 21, 2024
• Lead Manager: Horizon Management Private Limited
• Registrar: Mas Services Limited
• Market Maker: Giriraj Stock Broking